Skip to Content

EAN24: Efgartigimod in Generalized Myasthenia Gravis are Well Tolerated and Efficacious

The ADAPT study has provided interesting evidence supporting the use of efgartigimod in treating generalized myasthenia gravis. Efgartigimod, an FcRn antagonist, selectively reduces pathogenic IgG antibodies, resulting in clinically meaningful improvements in both function and muscle strength.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top